Viking Therapeutics is a clinical-stage company developing a targeted obesity drug that is not yet approved, with its lead program currently in Phase 3 testing.
Viking’s investment case rests on subcutaneous VK2735 translating Phase 2 weight loss into durable efficacy and safety in VANQUISH. Management says current resources support completion of ongoing Phase 3 obesity trials, following completed equity and debt financing. Oral VK2735’s separate SUNRISE program and exploratory maintenance development offer additional opportunities. VANQUISH results remain the central clinical decision, with extension studies planned to assess longer-term benefit and less-frequent dosing.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: VANQUISH demonstrates pivotal efficacy and safety
Do VANQUISH-1 and VANQUISH-2 demonstrate convincing weight loss and acceptable safety over 78 weeks in their respective populations?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Cash supports pivotal development; VANQUISH results remain central
Two fully enrolled Phase 3 trials plus an oral formulation in Phase 3 pipeline — thesis turns on whether VANQUISH efficacy data can carve share from Wegovy and Zepbound
VENTURE-Oral Phase 2 primary/secondary endpoints achieved
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: VK2735
Disease areas: Neurology and pain, Liver and digestive diseases, Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
11 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.